Evidence map›Paper›PMID 35086823›Full record

SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Circulating Sex Hormone Levels and Colon Cancer Risk in Men: A Nested Case-Control Study and Meta-Analysis.

Justin Harbs, Sabina Rinaldi, Audrey Gicquiau, Pekka Keski-Rahkonen, Nagisa Mori, Xijia Liu, Rudolf Kaaks, Verena Katzke, Matthias B Schulze, Claudia Agnoli and 16 more

Open access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 15 institutions in 9 countries.

Justin HarbsDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
Sabina RinaldiInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Audrey GicquiauInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Pekka Keski-RahkonenInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Nagisa MoriInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Xijia LiuDepartment of Statistics, Umeå University, Umeå, Sweden.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-3751-3929
Verena KatzkeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-6509-6555
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.ORCID 0000-0002-0830-5277
Claudia AgnoliEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.ORCID 0000-0003-4472-1179
Rosario TuminoCancer Registry and Histopathology Department, Provincial Health Authority (ASP 7), Ragusa, Italy.ORCID 0000-0003-2666-414X
Bas Bueno-de-MesquitaCentre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Marta Crous-BouUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Maria-Jose SánchezEscuela Andaluza de Salud Pública (EASP), Granada, Spain.ORCID 0000-0003-4817-0757
Amaia AizpuruaMinistry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain.
María-Dolores ChirlaqueCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Aurelio Barricarte GurreaCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-9571-0763
Eleanor L WattsCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-9229-2589
Sofia ChristakoudiDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0002-8452-8472
Elisabete WeiderpassInternational Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0003-2237-0128
Marc J GunterInternational Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0001-5472-6761
Bethany Van GuelpenDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.ORCID 0000-0002-9692-101X
Neil MurphyInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Sophia HarlidDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.ORCID 0000-0001-8540-6891
Centre international de recherche sur le cancer · FRUmeå University · SEGerman Cancer Research Center · DEUniversity of Oxford · GBBasque Government · ESFondazione IRCCS Istituto Nazionale dei Tumori · ITHarvard University · USInstituto de Salud Pública de Navarra · ESInstituto Murciano de Investigación Biosanitaria · ESKing's College London · GBNational Institute for Public Health and the Environment · NLRegional Health · USUniversidad de Granada · ESUniversity of Ioannina · GRUniversity of Potsdam · DE

Funding

Cancer Research UK 14136Cancer Research UK 29017Cancer Research UK C8221/A29017Department of HealthMedical Research Council 1000143Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1World Health Organization 001
6 · The paper itself

Abstract

backgroundEndogenous sex hormones may contribute to higher colorectal cancer incidence rates in men compared with women, but despite an increased number of studies, clear evidence is lacking.

methodsWe conducted a comprehensive nested case-control study of circulating concentrations of sex hormones, sex hormone precursors, and sex hormone binding globulin (SHBG) in relation to subsequent colon cancer risk in European men. Concentrations were measured using liquid LC/MS-MS in prospectively collected plasma samples from 690 cases and 690 matched controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS) cohorts. Multivariable conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). In addition, we conducted a meta-analysis of previous studies on men.

resultsCirculating levels of testosterone (OR, 0.68; 95% CI, 0.51-0.89) and SHBG (OR, 0.77; 95% CI, 0.62-0.96) were inversely associated with colon cancer risk. For free testosterone, there was a nonsignificant inverse association (OR, 0.83; 95% CI, 0.58-1.18). In a dose-response meta-analysis of endogenous sex hormone levels, inverse associations with colorectal/colon cancer risk were found for testosterone [relative risks (RR) per 100 ng/dL = 0.98; 95% CI, 0.96-1.00; I2 = 22%] and free testosterone (RR per 1 ng/dL = 0.98; 95% CI, 0.95-1.00; I2 = 0%).

conclusionsOur results provide suggestive evidence for the association between testosterone, SHBG, and male colon cancer development. IMPACT: Additional support for the involvement of sex hormones in male colon cancer.

Indexed as

Colonic NeoplasmsSex Hormone-Binding GlobulinCase-Control StudiesEstradiolFemaleGonadal Steroid HormonesHumansLogistic ModelsMaleProspective StudiesRisk FactorsTestosteroneEstradiolGonadal Steroid HormonesSex Hormone-Binding GlobulinTestosterone

Identifiers

PMID35086823
PMCPMC9381125
OpenAlexW4210292526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.